BioSpace News Archive

Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions

AlpVision SA, a pioneering information and communication technology company and a global leader in advanced signal processing applications, announces at the AI summit in London the release plan of bioserver.net, a new cloud computing service based on Biological Neural Networks.

Eighty-six percent of AARP members support the administration’s proposed rule to reform the rebate system in Medicare Part D, according to a nationwide Morning Consult survey commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

CutisPharma, Inc. announced its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.

Harbour BioMed and Erasmus MC, University Medical Center Rotterdam announced that they have signed a 10-year Memorandum of Understanding to enable a broad range of joint basic, translational and clinical research activities aimed at developing next generation biotherapeutics for the treatment of cancer and immunological diseases.

Highly engineered solutions that connect, control and innovate to move flight forward.

Nonalcoholic Steatohepatitis will next year be the number one cause of liver transplants

Publication demonstrates specific U2AF1 splicing factor mutations induce oncogenic IRAK4-L isoform and activate innate immune pathways in myeloid malignancies

IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV’s lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda® (pembrolizumab).

Following the announcement of the acquisition of emapalumab and related assets, Sobi™ intends to carry out a reorganisation to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology.